U.S. Markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
22.48-0.26 (-1.14%)
At close: 4:00PM EDT

22.48 0.00 (0.00%)
After hours: 4:53PM EDT

People also watch
TGTXPTLAFOLDSGYPOCUL
  • A
    Anna
    Anna
    Below: @peter thanks for comment and sending OMER your IR Q?. Let me explain the kidney and how to interpret this results OMS721 is getting. Kidneys are suppose to filter waste into urine but preserve valuable protein in our blood. The more damage a kidney have the more protein it spills into the urine. The reduction in urine protein in OMS721 treated patients is remarkable, likely meaning there's some healing going on in the kidney. GFR is the rate at which the kidney is able to process fluid through it's system. The lower the GFR the greater the damage of the kidney, like a water tap giving you less and less water from corroded pipe. So a higher GFR in OMS721 tx'ed pt's is reopening the damage or corrosion of the pipes. Both remarkable. All this and no serious side effects. A game changer in IgA neph. treatment, so eventually less people need dialyses as now 10 % of people who need dialysis got there because they had IgA nephr.
  • o
    onyxpig
    onyxpig
    3,450,000 shares were spoken for before the announcement! Count on it! All good as no borrowing (interest expense) necessary!!!! $30 by year end IMO
  • d
    david
    david
    How about everybody go have a couple of gin and tonics , turn off the market , get drunk and then wake up to being rich.
    It's just time-got to believe.

    BLOCKBUSTER!
  • B
    Brian
    Brian
    I agree with Duke. Anyone worrying a bit should really think whats going on. We get good news about OMS721 with the trials and we beat expectations from wallstreet on the 2Q revs. Now we only dilute 3 million shares and will get around $70+ million in cash. Not to forget the 2 tranches we have left and growing revs from Omidria. Big deal that our OS will go from 44 million to close to 48 million. Look at ALXN. Yes they have good revs right now, but they have close to 225 million shares OS! And many other small and big biotechs have 100M, 200m and 300M+. I know this is a different field, but PCLN did a reverse split several years back bringing their OS down to about 50 million. Their stock went from $35 to $2000 a shares in those several years. They have about $8 billion in revs a year, but if OMER does only 1/4 of that I think many here would be VERY happy. Its still a road ahead, but we are on our way!
  • b
    ben
    ben
    Should be getting another PR today or tomorrow.
  • b
    ben
    ben
    So now how soon do we announce a European partner for Omidria?
  • T
    The Duke
    The Duke
    holding up well in a down day for biotechs and market. add here if you have cash
  • J
    J
    J
    Why is there speculation that EU partnership is being announced today/soon?
  • b
    ben
    ben
    Secondary 3.45 million shares about 7.5% dilution and pps is down about 3% not bad at all.
  • D
    Dan
    Dan
    I say secondary done and will have $$$ and let's enjoy the ride. Don't worry about the dips.
  • A
    Anna
    Anna
    This looks like a bargain to me, shares diluted 3 mil. of 44 mil or 6% but stock down 8%. Big drug news today on Business Wire reports OMS721 showed 1 year continued kidney improvement in 3 of 4 patients treated for IgA nephropathy and minimal side effect. There's no drug available for this condition, 190,000 people in the US have this condition and results showed there may be benefit of repeated dosing with OMS721! This is potentially great news. Remember the FDA has occasionally approved new drugs after Phase 2 results when there's no other treatment available. Hope price holds as it should and we might not need a year to get this approved. Shorts beware!
  • R
    Rowedeo
    Rowedeo
    See me sweating? Nope. This company is gravy, baby!!
  • A
    Anna
    Anna
    One more point on the 4 patients 1 year out results, 1 of 4 didn't maintain the kidney improvement seen earlier. That's good and bad news. Possibly bad for the patient temporarily but re dosing (selling more drug) may regain the improvement, which would increase revenues significantly. Total cures by drugs like Gilead's Hep C treatment is great for patient and temporarily good for company but then there's less and less patients to treat, hence Gilead's downturn for last 9? months. Might not happen with OMS721, who knows?
  • T
    Timothy
    Timothy
    Potential for billions o dollars in sales in the next 1-2 yrs-----more as time goes by. This could easily be 65 sh or more very soon and much higher than that if all cylinders hit
  • T
    The Duke
    The Duke
    Everything is fine. Relax people.
  • G
    Gary
    Gary
    Last chance to buy under the offering price!
  • a
    ariadinvestor
    ariadinvestor
    humour412, I bought OMER not that you've been spamming about it on AUPH msg board but that my friend Dr. Hu recommended it before you started to spam about it. I won't add any OMER shares. I doubt OMER is a good stock because of your spamming about OMER & trash PLX on $AUPH conversation. Spammers like you usually spam a garbage stock on other stocks' msg boards. I swear to God I own OMER shares. But I doubt you own any. You are a pathetic spammer + basher + fact-twister + liar + rude poster. Does this post violate Yahoo's TOS?
    Imagesupersexyactioncomics
  • B
    Brian
    Brian
    With what the doctor said yesterday and now we have plenty of cash on hand....the stock goes down? Too many traders and amateur investors.
  • J
    JohnnyB
    JohnnyB
    Call me stupid, but i think with the 100MIL IN THE BANK, we go back around 25. in short order.
  • o
    onyxpig
    onyxpig
    A little hint...Dr.D believes his company is worth way more than $22.75. Just sayin'. He hates shorts and loves the game IMO. Longs win...longs win